Calidi Biotherapeutics to Present at 2024 ASCO Annual Meeting

SAN DIEGO—Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology firm focused on innovative immunotherapies, has announced the acceptance of three abstracts for presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. This prestigious event will be held from May 31 to June 4, 2024, in Chicago, Illinois.

The presentations will showcase significant advancements in Calidi’s ongoing research and clinical trials. One of the key highlights will be an update from a Phase 1 study led by City of Hope, which examines Calidi's CLD-101 program aimed at treating recurrent high-grade glioma. This study, now moving into its fourth cohort, is part of Calidi’s NeuroNova program. The CLD-101 therapy utilizes tumor-tropic neural stem cells (NSCs) to deliver the oncolytic adenovirus CRAd-S-pk7 directly to tumor sites, representing a sophisticated approach to targeting cancer cells.

In addition to the clinical update on CLD-101, Calidi will present preclinical data on two other promising programs. The first is their RTNova delivery platform, which represents a novel systemic enveloped oncolytic virotherapy designed to target a wide range of tumor sites throughout the body. The second is the CLD-201 program, which is anticipated to commence its Phase 1 trial in the latter half of 2024, contingent upon securing additional funding.

The detailed schedule for the poster presentations at the ASCO meeting is as follows:

1. Title: Phase 1 study of multiple intracerebral doses of a neural stem cell-based oncolytic virotherapy for treatment of recurrent high-grade gliomas
- Abstract Number: TPS2102
- Session Title: Central Nervous System Tumors
- Session Date and Time: June 1, 2024, from 9:00 AM to 12:00 PM CDT

2. Title: Transforming tumor immune microenvironments with a novel systemic enveloped oncolytic virotherapy targeting all tumor sites
- Abstract Number: 2559
- Session Title: Developmental Therapeutics – Immunotherapy
- Session Date and Time: June 1, 2024, from 9:00 AM to 12:00 PM CDT

3. Title: Non-clinical evidence supporting the upcoming CLD-201 clinical trial: Cell-based oncolytic virotherapy for multiple solid tumors
- Abstract Number: 2553
- Session Title: Developmental Therapeutics - Immunotherapy
- Session Date and Time: June 1, 2024, from 9:00 AM to 12:00 PM CDT

About Calidi Biotherapeutics

Calidi Biotherapeutics (NYSE American: CLDI) is an innovative immuno-oncology company at the clinical stage, focused on harnessing the immune system to combat cancer. The company’s proprietary technology involves using potent allogeneic stem cells to deliver oncolytic viruses, aiming to treat various cancers, including high-grade gliomas and solid tumors. Calidi's approach includes off-the-shelf, universal cell-based delivery platforms that enhance the efficacy and safety of oncolytic viruses. They also have preclinical enveloped virotherapies designed to target widespread solid tumors, potentially offering solutions for metastatic disease. Calidi Biotherapeutics is based in San Diego, California.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!